Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00471419

Enrollment

750

Registered

2007-05-09

Start date

2006-07-31

Completion date

2007-08-31

Last updated

2012-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Brief summary

The purpose of this study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.

Interventions

DRUGRimexolone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* documented dry eye history * ocular symptoms * tear use * dry eye ocular signs

Exclusion criteria

* Under 18

Design outcomes

Primary

Measure	Time frame
Corneal staining; dry eye sympton	Immediate

Secondary

Measure	Time frame
Corneal staining; dry eye sympton	Prolonged

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026